Objectives:
- Discuss the rationale and current use of hypomethylating agents in acute myeloid leukemia
- Describe a big-data based evaluation of current hypomethylating agent use in AML
- Outline a trial of guadecitabine in previously untreated TP53-mutant and adverse-risk AML
Objectives:
- Immune related adverse events (irAEs) and quick pathophysiology
- Current recommendations on management of irAEs
- Predicting onset and severity of irAEs
- Collaboration between Oncology and Rheumatology for future research
Session date:
10/09/2017 - 12:00pm to 1:00pm CDT
Location:
UCMC
5841 South Maryland Avenue
MC2115, Conference Room E-215
Chicago, IL
60637
United States
See map: Google Maps
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Speaker Name:
Andrew Hantel, MD 2nd Year Fellow - Section of Hematology/Oncology and Pankti Reid, MD, MPH 2nd Year Fellow – Department of Rheumatology; 1st Year Fellow – Department of Clinical Pharmacology & Pharmacogenomics - University of Chicago Medicine